Investor updates Keyword Search Clear 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Published on: 29 December 2014 Invitation to Roche's Full Year Results 2014 Roche will publish its Full Year Results for 2014 prior to the opening of the Swiss Stock Exchange on 28 January 2015. more Published on: 19 December 2014 Roche provides update on gantenerumab development programme Roche today announced the decision to discontinue SCarlet RoAD (WN25203), a phase III study of investigational anti-amyloid medicine gantenerumab in prodromal (pre-dementia) Alzheimer's disease, ... more Published on: 19 December 2014 Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, ... more Published on: 12 December 2014 Changes in Roche Board of Directors and enlarged Corporate Executive Committee At its December meeting, the Board of Directors (BoD) of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015. more Published on: 9 December 2014 Roche presents data for hemophilia A therapy ACE910 Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual ... more Published on: 8 December 2014 Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark Roche announced today the commercial availability of the cobas HIV-1 and cobas HCV assays for use on the cobas 6800/8800 Systems-expanding the menu on the newest molecular diagnostic platforms from ... more Published on: 5 December 2014 Roche to present clinical data from six different medicines at ASH Roche announced today that new data on four investigational medicines and investigational uses for two approved hematology medicines will be presented during the 56th American Society of Hematology ... more Published on: 2 December 2014 Roche acquires Ariosa Diagnostics and enters the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets Roche today announced the acquisition of Ariosa Diagnostics, Inc. (Ariosa), a privately-held company based in San Jose, California, USA. Ariosa is a molecular diagnostics testing service provider ... more Published on: 17 November 2014 FDA approves Roche’s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ... more Published on: 13 November 2014 Roche Receives FDA Clearance for Strep A Test on cobas Liat System Roche today announced that the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas Strep A test for the detection of group A streptococcus bacterial (Strep A) DNA in ... more Published on: 6 November 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting Following last year's inaugural conference, we are once again delighted to invite you to the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday 17 November 2014 at the ... more Published on: 5 November 2014 Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China Roche announced today it will invest 450 million Swiss Francs over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China. more Published on: 29 October 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting Following last year's inaugural conference, we are once again delighted to invite you to the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday 17 November 2014 at the ... more Published on: 24 October 2014 CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis (IPF), strengthening mortality benefit and reinforcing safety profile Roche announced today that Esbriet® (pirfenidone) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an update to its European prescribing information, ... more Published on: 22 October 2014 Roche invests for the future in its Basel site Today Roche presented development plans for its Basel site. Over the next 10 years, Roche will invest 3 billion Swiss francs in the construction of a new research and development centre for around ... more Published on: 16 October 2014 Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER, stable in Swiss francs; 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for ... more Published on: 16 October 2014 FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) in the United States. IPF is a fatal ... more Published on: 9 October 2014 Reminder: Invitation to Roche's Third Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Thursday October 16th, 2014. more Published on: 9 October 2014 Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting Following last year’s inaugural conference, we are once again delighted to invite you to the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday 17 November 2014 at the ... more Published on: 8 October 2014 FDA grants Priority Review for Lucentis in diabetic retinopathy Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis ... more Published on: 29 September 2014 Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab) Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC. Roche also presented monotherapy data for MPDL3280A ... more Published on: 29 September 2014 Roche presents encouraging update on metastatic bladder cancer data for anti-PDL1 medicine (MPDL3280A) Roche presented an update on data for the use of its investigational cancer immunotherapy, MPDL3280A (anti-PDL1 or anti Programmed Death Ligand-1) in patients with mUBC at the European Society for ... more Published on: 29 September 2014 Roche’s investigational combination of cobimetinib plus Zelboraf® (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone Roche today announced positive data from the coBRIM Phase III study. The results showed that people with previously untreated BRAF V600 mutation-positive, advanced melanoma who received the MEK ... more Published on: 29 September 2014 Roche purchases shares in tender offer for InterMune, Inc. Roche and InterMune, Inc. (NASDAQ: ITMN) today announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender ... more Published on: 28 September 2014 Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives ... more Published on: 26 September 2014 Roche launches Global Access Program for HIV viral load testing Roche announced today the launch of a new Global Access Program for HIV viral load testing, created in partnership with UNAIDS, the joint United Nations Program on HIV/AIDS, the Clinton Health Access ... more Published on: 25 September 2014 Roche's Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies Roche today announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following ... more Published on: 22 September 2014 Reminder: Invitation to Roche's investor science conference call from ESMO 2014 We kindly invite investors and analysts to participate in a conference call to discuss new clinical data on the Roche oncology products and pipeline presented during the 2014 annual meeting of the ... more Published on: 17 September 2014 Roche to present latest oncology advances during ESMO 2014 Congress Roche announced today that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 ... more Published on: 16 September 2014 Invitation to Roche's Third Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Thursday October 16th, 2014. more Published on: 15 September 2014 Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA) Roche today announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy (GA), the advanced form of age-related macular degeneration ... more Published on: 11 September 2014 Roche again ranked most sustainable healthcare company in the Dow Jones Sustainability Indices For the sixth consecutive year, Roche has been recognised by the Dow Jones Sustainability Indices (DJSI) as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life ... more Published on: 8 September 2014 Roche's RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA) Roche announced today that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated ... more Published on: 5 September 2014 Launch of the Anti-Cancer Agent / ALK Inhibitor “Alecensa” in Japan Please find attached a press release by Chugai. more Published on: 4 September 2014 Roche announces change in Board of Directors Roche announced today that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his ... more Published on: 2 September 2014 Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity Roche announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening in markets ... more Published on: 29 August 2014 Roche commences tender offer for InterMune, Inc. for US$74.00 per share in cash Roche today announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share. The tender offer is being made pursuant ... more Published on: 26 August 2014 Invitation to Roche's investor science conference call from ESMO 2014 We kindly invite investors and analysts to participate in a conference call to discuss new clinical data on the Roche oncology products and pipeline presented during the 2014 annual meeting of the ... more Published on: 25 August 2014 Reminder: Invitation to Roche investor conference call on the acquisition of InterMune We kindly invite investors and analysts to participate in a conference call to discuss the announcement that Roche and InterMune, Inc. have entered into a definitive merger agreement for Roche to ... more Published on: 24 August 2014 Roche and InterMune reach definitive merger agreement Roche and InterMune, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This ... more Published on: 15 August 2014 FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of ... more Published on: 6 August 2014 EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a ... more Published on: 29 July 2014 Roche's Gazyvaro approved in Europe for patients with the most common type of leukemia Roche today announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic ... more Published on: 28 July 2014 Roche's RoACTEMRA receives CHMP positive opinion in Europe for use in patients with early rheumatoid arthritis (RA) not previously treated with methotrexate (MTX) Roche announced today that RoACTEMRA (tocilizumab, also known as ACTEMRA) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in Europe in patients ... more Published on: 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates, -1% in Swiss francs more Published on: 22 July 2014 Reminder: Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 We are pleased to invite you to an analyst event on Tuesday, 29 July 2014 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more Published on: 22 July 2014 FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin ... more Published on: 17 July 2014 Reminder: Invitation to Roche's Half Year Results 2014 Roche will publish its Half Year Results for 2014 prior to the opening of the Swiss Stock Exchange on 24th July, 2014. more Published on: 16 July 2014 Roche announces phase II clinical results of crenezumab in Alzheimer’s disease Proof of concept study in mild-to-moderate Alzheimer’s disease did not meet its co-primary endpoints. Positive trend in cognition observed with greater effect in people with mild disease who received ... more Published on: 15 July 2014 FDA grants Roche's Avastin Priority Review for certain types of cervical cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin ... more Published on: 14 July 2014 Roche's investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening Data from the coBRIM study will be presented at an upcoming medical meeting. Roche plans to submit these data to health authorities around the world. Roche announced today that the Phase III coBRIM ... more Published on: 4 July 2014 Japan becomes first country to approve Roche's alectinib for people with a specific form of advanced lung cancer Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib. Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has ... more Published on: 2 July 2014 Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 We are pleased to invite you to an analyst event on Tuesday, 29 July 2014 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more Published on: 2 July 2014 Roche announces definitive agreement to acquire Seragon Pharmaceuticals Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer. Roche announced today that Genentech, a member of the Roche Group, has entered into a ... more Published on: 30 June 2014 Roche launches fully automated urine testing analyzer for enhanced result reliability and staff safety Roche announced today the launch of cobas 6500, a fully automated urine testing system that consists of two modular analyzers combining urine strip testing and digital urinary microscopy. The system ... more Published on: 27 June 2014 CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Avastin (bevacizumab) in combination with ... more Published on: 26 June 2014 Invitation to Roche's Half Year Results 2014 Roche will publish its Half Year Results for 2014 prior to the opening of the Swiss Stock Exchange on 24th July, 2014. more Published on: 16 June 2014 Roche Children's Walk 2014: Roche employees participate in sponsored walk to support vulnerable children in Malawi and around the world Today, Roche employees at more than 120 company sites around the world have been showing their solidarity with children in need by raising funds through sponsored walks. The donations will be used to ... more Published on: 4 June 2014 Save the date: Swiss Sustainability Leaders - 2nd Annual Meeting SRI Conference 2014 Following last year's inaugural conference, we are once again delighted to announce the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday, 17 November 2014 at the Roche ... more Published on: 2 June 2014 The combination of Roche's Avastin and Tarceva helped people with a specific form of lung cancer live longer without their disease worsening Phase II study in Japanese patients with a specific type of lung cancer meets primary endpoint of improved progression-free survival with the combination of Avastin and Tarceva compared to Tarceva ... more Published on: 2 June 2014 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2014 We are pleased to invite you to an analyst event on Tuesday, 29 July 2014 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more Published on: 2 June 2014 Roche acquires Genia Technologies to strengthen next generation sequencing pipeline Roche announced today the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA. Genia is developing a single-molecule, semiconductor ... more Published on: 1 June 2014 Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis (PVNS) Encouraging results from Phase 1 study in a rare disease with high unmet medical need. FDA has granted orphan drug designation for RG7155 in the treatment of PVNS. Roche announced today that the ... more Published on: 31 May 2014 Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate GDC-0199/ABT-199 combined with rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) shows encouraging activity. Head-to-head ROMULUS data in R/R non-Hodgkin lymphoma (NHL) ... more Published on: 31 May 2014 Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study The U.S. Food and Drug Administration (FDA) has granted first Breakthrough Therapy Designation in bladder cancer for MPDL3280A. Roche today announced results from a Phase I open-label study that ... more Published on: 23 May 2014 CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of ... more Published on: 23 May 2014 Reminder: Invitation to Roche Analyst Event at ASCO 2014 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 14 May 2014 Roche to present new data on 27 different medicines at ASCO Roche today announced that new data on nine approved and 18 investigational medicines will be presented during the 50th American Society of Clinical Oncology (ASCO) Annual Meeting. Of the more than ... more Published on: 7 May 2014 Roche presents final Phase 1b data on its investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma at EADO 2014 BRIM7 study shows that cobimetinib and Zelboraf (vemurafenib) can be co-administered and provided a median progression-free survival of 13.7 months in BRAF inhibitor-naive patients. Confirmatory ... more Published on: 30 April 2014 Invitation to Roche Analyst Event at ASCO 2014 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 28 April 2014 Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis Roche announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received approval from the European Commission for the treatment of moderate to severe rheumatoid arthritis (RA) ... more Published on: 25 April 2014 FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer Roche announced today that the U.S. Food and Drug Administration (FDA) approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women ... more Published on: 17 April 2014 Launch of the Anti-Cancer Agent “Kadcyla®” in Japan Please find attached a press release by Chugai. more Published on: 15 April 2014 Roche with good start in 2014 Continued growth due to recently launched medicines more Published on: 8 April 2014 Reminder: Invitation to Roche's First Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Tuesday April 15th, 2014. more Published on: 7 April 2014 Roche acquires IQuum to strengthen offerings in molecular diagnostics IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics. Roche announced today the acquisition of IQuum, Inc. based in Marlborough, Massachusetts, ... more Published on: 28 March 2014 Save the date: Roche Analyst Event at ASCO 2014 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more Published on: 28 March 2014 Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma Roche announced today that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse ... more Published on: 24 March 2014 FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives Roche today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is ... more Published on: 18 March 2014 Invitation to Roche's First Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Tuesday April 15th, 2014. more Published on: 13 March 2014 FDA Advisory committee unanimously recommends Roche's HPV Test as primary screening tool for detection of women at high risk for cervical cancer Roche announced today that the U.S. Food and Drug Administration (FDA) Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas HPV ... more Published on: 7 March 2014 New Roche test helps specialists to identify syphilis in routine samples and donated blood Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease. Roche today announced the market availability of the Elecsys Syphilis ... more Published on: 5 March 2014 Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma New data show lebrikizumab appears most effective in a specific sub-population of patients with high levels of periostin, a protein that indicates a certain type of asthma. The biomarker periostin ... more Published on: 4 March 2014 Roche Annual General Meeting 2014 Christoph Franz elected as Chairman of the Board of Directors; 27th consecutive dividend increase; Shareholders approve all proposals by the Board of Directors more Published on: 3 March 2014 Roche provides update on phase III study of onartuzumab in people with specific type of lung cancer Roche announced today that an independent data monitoring committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy. more Published on: 26 February 2014 Reminder: Upcoming changes to the Roche ADR (RHHBY) Roche, as previously announced on 10 February 2014, plans to implement a change to its US ADR programme (RHHBY, CUSIP 771195104) in the near future. The planned change comprises a change in the ADR ... more Published on: 10 February 2014 Upcoming changes to the Roche ADR (RHHBY) Roche plans to implement a change to its US ADR programme (RHHBY, CUSIP 771195104) in the near future. The planned change comprises a change in the ADR ratio from now 4 (four) ADRs (RHHBY) per 1 ... more Published on: 30 January 2014 Roche delivers strong 2013 results Group sales rise 6% to 46.8 billion Swiss francs; Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin, MabThera/Rituxan, Actemra/RoActemra and Lucentis. Diagnostics ... more Published on: 24 January 2014 CHMP recommends EU approval of a new formulation of Roche’s MabThera for patients with non-Hodgkin lymphoma Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve MabThera (rituximab) 1400mg solution for subcutaneous (SC) ... more Published on: 21 January 2014 Reminder: Invitation to Roche's Full Year Results for 2013 Roche will publish its Full Year Results for 2013 prior to the opening of the Swiss Stock Exchange on 30 January 2014. more Published on: 21 January 2014 Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia Two phase III studies evaluating bitopertin for persistent, predominant negative symptoms of schizophrenia did not meet their primary endpoints; third study is ongoing. more
Published on: 29 December 2014 Invitation to Roche's Full Year Results 2014 Roche will publish its Full Year Results for 2014 prior to the opening of the Swiss Stock Exchange on 28 January 2015. more
Published on: 19 December 2014 Roche provides update on gantenerumab development programme Roche today announced the decision to discontinue SCarlet RoAD (WN25203), a phase III study of investigational anti-amyloid medicine gantenerumab in prodromal (pre-dementia) Alzheimer's disease, ... more
Published on: 19 December 2014 Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, ... more
Published on: 12 December 2014 Changes in Roche Board of Directors and enlarged Corporate Executive Committee At its December meeting, the Board of Directors (BoD) of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015. more
Published on: 9 December 2014 Roche presents data for hemophilia A therapy ACE910 Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual ... more
Published on: 8 December 2014 Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark Roche announced today the commercial availability of the cobas HIV-1 and cobas HCV assays for use on the cobas 6800/8800 Systems-expanding the menu on the newest molecular diagnostic platforms from ... more
Published on: 5 December 2014 Roche to present clinical data from six different medicines at ASH Roche announced today that new data on four investigational medicines and investigational uses for two approved hematology medicines will be presented during the 56th American Society of Hematology ... more
Published on: 2 December 2014 Roche acquires Ariosa Diagnostics and enters the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets Roche today announced the acquisition of Ariosa Diagnostics, Inc. (Ariosa), a privately-held company based in San Jose, California, USA. Ariosa is a molecular diagnostics testing service provider ... more
Published on: 17 November 2014 FDA approves Roche’s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ... more
Published on: 13 November 2014 Roche Receives FDA Clearance for Strep A Test on cobas Liat System Roche today announced that the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas Strep A test for the detection of group A streptococcus bacterial (Strep A) DNA in ... more
Published on: 6 November 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting Following last year's inaugural conference, we are once again delighted to invite you to the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday 17 November 2014 at the ... more
Published on: 5 November 2014 Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China Roche announced today it will invest 450 million Swiss Francs over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China. more
Published on: 29 October 2014 Reminder: Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting Following last year's inaugural conference, we are once again delighted to invite you to the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday 17 November 2014 at the ... more
Published on: 24 October 2014 CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis (IPF), strengthening mortality benefit and reinforcing safety profile Roche announced today that Esbriet® (pirfenidone) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an update to its European prescribing information, ... more
Published on: 22 October 2014 Roche invests for the future in its Basel site Today Roche presented development plans for its Basel site. Over the next 10 years, Roche will invest 3 billion Swiss francs in the construction of a new research and development centre for around ... more
Published on: 16 October 2014 Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER, stable in Swiss francs; 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for ... more
Published on: 16 October 2014 FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) in the United States. IPF is a fatal ... more
Published on: 9 October 2014 Reminder: Invitation to Roche's Third Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Thursday October 16th, 2014. more
Published on: 9 October 2014 Swiss Sustainability Leaders SRI Conference 2014 - 2nd Annual Meeting Following last year’s inaugural conference, we are once again delighted to invite you to the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday 17 November 2014 at the ... more
Published on: 8 October 2014 FDA grants Priority Review for Lucentis in diabetic retinopathy Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis ... more
Published on: 29 September 2014 Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab) Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC. Roche also presented monotherapy data for MPDL3280A ... more
Published on: 29 September 2014 Roche presents encouraging update on metastatic bladder cancer data for anti-PDL1 medicine (MPDL3280A) Roche presented an update on data for the use of its investigational cancer immunotherapy, MPDL3280A (anti-PDL1 or anti Programmed Death Ligand-1) in patients with mUBC at the European Society for ... more
Published on: 29 September 2014 Roche’s investigational combination of cobimetinib plus Zelboraf® (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone Roche today announced positive data from the coBRIM Phase III study. The results showed that people with previously untreated BRAF V600 mutation-positive, advanced melanoma who received the MEK ... more
Published on: 29 September 2014 Roche purchases shares in tender offer for InterMune, Inc. Roche and InterMune, Inc. (NASDAQ: ITMN) today announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender ... more
Published on: 28 September 2014 Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives ... more
Published on: 26 September 2014 Roche launches Global Access Program for HIV viral load testing Roche announced today the launch of a new Global Access Program for HIV viral load testing, created in partnership with UNAIDS, the joint United Nations Program on HIV/AIDS, the Clinton Health Access ... more
Published on: 25 September 2014 Roche's Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies Roche today announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following ... more
Published on: 22 September 2014 Reminder: Invitation to Roche's investor science conference call from ESMO 2014 We kindly invite investors and analysts to participate in a conference call to discuss new clinical data on the Roche oncology products and pipeline presented during the 2014 annual meeting of the ... more
Published on: 17 September 2014 Roche to present latest oncology advances during ESMO 2014 Congress Roche announced today that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 ... more
Published on: 16 September 2014 Invitation to Roche's Third Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Thursday October 16th, 2014. more
Published on: 15 September 2014 Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA) Roche today announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy (GA), the advanced form of age-related macular degeneration ... more
Published on: 11 September 2014 Roche again ranked most sustainable healthcare company in the Dow Jones Sustainability Indices For the sixth consecutive year, Roche has been recognised by the Dow Jones Sustainability Indices (DJSI) as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life ... more
Published on: 8 September 2014 Roche's RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA) Roche announced today that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated ... more
Published on: 5 September 2014 Launch of the Anti-Cancer Agent / ALK Inhibitor “Alecensa” in Japan Please find attached a press release by Chugai. more
Published on: 4 September 2014 Roche announces change in Board of Directors Roche announced today that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his ... more
Published on: 2 September 2014 Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity Roche announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening in markets ... more
Published on: 29 August 2014 Roche commences tender offer for InterMune, Inc. for US$74.00 per share in cash Roche today announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share. The tender offer is being made pursuant ... more
Published on: 26 August 2014 Invitation to Roche's investor science conference call from ESMO 2014 We kindly invite investors and analysts to participate in a conference call to discuss new clinical data on the Roche oncology products and pipeline presented during the 2014 annual meeting of the ... more
Published on: 25 August 2014 Reminder: Invitation to Roche investor conference call on the acquisition of InterMune We kindly invite investors and analysts to participate in a conference call to discuss the announcement that Roche and InterMune, Inc. have entered into a definitive merger agreement for Roche to ... more
Published on: 24 August 2014 Roche and InterMune reach definitive merger agreement Roche and InterMune, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This ... more
Published on: 15 August 2014 FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of ... more
Published on: 6 August 2014 EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a ... more
Published on: 29 July 2014 Roche's Gazyvaro approved in Europe for patients with the most common type of leukemia Roche today announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic ... more
Published on: 28 July 2014 Roche's RoACTEMRA receives CHMP positive opinion in Europe for use in patients with early rheumatoid arthritis (RA) not previously treated with methotrexate (MTX) Roche announced today that RoACTEMRA (tocilizumab, also known as ACTEMRA) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in Europe in patients ... more
Published on: 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates, -1% in Swiss francs more
Published on: 22 July 2014 Reminder: Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 We are pleased to invite you to an analyst event on Tuesday, 29 July 2014 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more
Published on: 22 July 2014 FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin ... more
Published on: 17 July 2014 Reminder: Invitation to Roche's Half Year Results 2014 Roche will publish its Half Year Results for 2014 prior to the opening of the Swiss Stock Exchange on 24th July, 2014. more
Published on: 16 July 2014 Roche announces phase II clinical results of crenezumab in Alzheimer’s disease Proof of concept study in mild-to-moderate Alzheimer’s disease did not meet its co-primary endpoints. Positive trend in cognition observed with greater effect in people with mild disease who received ... more
Published on: 15 July 2014 FDA grants Roche's Avastin Priority Review for certain types of cervical cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin ... more
Published on: 14 July 2014 Roche's investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening Data from the coBRIM study will be presented at an upcoming medical meeting. Roche plans to submit these data to health authorities around the world. Roche announced today that the Phase III coBRIM ... more
Published on: 4 July 2014 Japan becomes first country to approve Roche's alectinib for people with a specific form of advanced lung cancer Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib. Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has ... more
Published on: 2 July 2014 Roche Analyst Event on Diagnostics Division at AACC 2014 Tuesday, 29 July 2014 We are pleased to invite you to an analyst event on Tuesday, 29 July 2014 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more
Published on: 2 July 2014 Roche announces definitive agreement to acquire Seragon Pharmaceuticals Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer. Roche announced today that Genentech, a member of the Roche Group, has entered into a ... more
Published on: 30 June 2014 Roche launches fully automated urine testing analyzer for enhanced result reliability and staff safety Roche announced today the launch of cobas 6500, a fully automated urine testing system that consists of two modular analyzers combining urine strip testing and digital urinary microscopy. The system ... more
Published on: 27 June 2014 CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Avastin (bevacizumab) in combination with ... more
Published on: 26 June 2014 Invitation to Roche's Half Year Results 2014 Roche will publish its Half Year Results for 2014 prior to the opening of the Swiss Stock Exchange on 24th July, 2014. more
Published on: 16 June 2014 Roche Children's Walk 2014: Roche employees participate in sponsored walk to support vulnerable children in Malawi and around the world Today, Roche employees at more than 120 company sites around the world have been showing their solidarity with children in need by raising funds through sponsored walks. The donations will be used to ... more
Published on: 4 June 2014 Save the date: Swiss Sustainability Leaders - 2nd Annual Meeting SRI Conference 2014 Following last year's inaugural conference, we are once again delighted to announce the 2014 Swiss Sustainability Leaders SRI Conference, which will be held on Monday, 17 November 2014 at the Roche ... more
Published on: 2 June 2014 The combination of Roche's Avastin and Tarceva helped people with a specific form of lung cancer live longer without their disease worsening Phase II study in Japanese patients with a specific type of lung cancer meets primary endpoint of improved progression-free survival with the combination of Avastin and Tarceva compared to Tarceva ... more
Published on: 2 June 2014 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2014 We are pleased to invite you to an analyst event on Tuesday, 29 July 2014 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual ... more
Published on: 2 June 2014 Roche acquires Genia Technologies to strengthen next generation sequencing pipeline Roche announced today the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA. Genia is developing a single-molecule, semiconductor ... more
Published on: 1 June 2014 Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis (PVNS) Encouraging results from Phase 1 study in a rare disease with high unmet medical need. FDA has granted orphan drug designation for RG7155 in the treatment of PVNS. Roche announced today that the ... more
Published on: 31 May 2014 Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate GDC-0199/ABT-199 combined with rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) shows encouraging activity. Head-to-head ROMULUS data in R/R non-Hodgkin lymphoma (NHL) ... more
Published on: 31 May 2014 Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study The U.S. Food and Drug Administration (FDA) has granted first Breakthrough Therapy Designation in bladder cancer for MPDL3280A. Roche today announced results from a Phase I open-label study that ... more
Published on: 23 May 2014 CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of ... more
Published on: 23 May 2014 Reminder: Invitation to Roche Analyst Event at ASCO 2014 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 14 May 2014 Roche to present new data on 27 different medicines at ASCO Roche today announced that new data on nine approved and 18 investigational medicines will be presented during the 50th American Society of Clinical Oncology (ASCO) Annual Meeting. Of the more than ... more
Published on: 7 May 2014 Roche presents final Phase 1b data on its investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma at EADO 2014 BRIM7 study shows that cobimetinib and Zelboraf (vemurafenib) can be co-administered and provided a median progression-free survival of 13.7 months in BRAF inhibitor-naive patients. Confirmatory ... more
Published on: 30 April 2014 Invitation to Roche Analyst Event at ASCO 2014 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 28 April 2014 Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis Roche announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received approval from the European Commission for the treatment of moderate to severe rheumatoid arthritis (RA) ... more
Published on: 25 April 2014 FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer Roche announced today that the U.S. Food and Drug Administration (FDA) approved the cobas HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women ... more
Published on: 17 April 2014 Launch of the Anti-Cancer Agent “Kadcyla®” in Japan Please find attached a press release by Chugai. more
Published on: 15 April 2014 Roche with good start in 2014 Continued growth due to recently launched medicines more
Published on: 8 April 2014 Reminder: Invitation to Roche's First Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Tuesday April 15th, 2014. more
Published on: 7 April 2014 Roche acquires IQuum to strengthen offerings in molecular diagnostics IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics. Roche announced today the acquisition of IQuum, Inc. based in Marlborough, Massachusetts, ... more
Published on: 28 March 2014 Save the date: Roche Analyst Event at ASCO 2014 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in ... more
Published on: 28 March 2014 Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma Roche announced today that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse ... more
Published on: 24 March 2014 FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives Roche today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is ... more
Published on: 18 March 2014 Invitation to Roche's First Quarter Sales 2014 Conference Call Roche will publish its Sales Results for the 1st Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Tuesday April 15th, 2014. more
Published on: 13 March 2014 FDA Advisory committee unanimously recommends Roche's HPV Test as primary screening tool for detection of women at high risk for cervical cancer Roche announced today that the U.S. Food and Drug Administration (FDA) Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas HPV ... more
Published on: 7 March 2014 New Roche test helps specialists to identify syphilis in routine samples and donated blood Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease. Roche today announced the market availability of the Elecsys Syphilis ... more
Published on: 5 March 2014 Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma New data show lebrikizumab appears most effective in a specific sub-population of patients with high levels of periostin, a protein that indicates a certain type of asthma. The biomarker periostin ... more
Published on: 4 March 2014 Roche Annual General Meeting 2014 Christoph Franz elected as Chairman of the Board of Directors; 27th consecutive dividend increase; Shareholders approve all proposals by the Board of Directors more
Published on: 3 March 2014 Roche provides update on phase III study of onartuzumab in people with specific type of lung cancer Roche announced today that an independent data monitoring committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy. more
Published on: 26 February 2014 Reminder: Upcoming changes to the Roche ADR (RHHBY) Roche, as previously announced on 10 February 2014, plans to implement a change to its US ADR programme (RHHBY, CUSIP 771195104) in the near future. The planned change comprises a change in the ADR ... more
Published on: 10 February 2014 Upcoming changes to the Roche ADR (RHHBY) Roche plans to implement a change to its US ADR programme (RHHBY, CUSIP 771195104) in the near future. The planned change comprises a change in the ADR ratio from now 4 (four) ADRs (RHHBY) per 1 ... more
Published on: 30 January 2014 Roche delivers strong 2013 results Group sales rise 6% to 46.8 billion Swiss francs; Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin, MabThera/Rituxan, Actemra/RoActemra and Lucentis. Diagnostics ... more
Published on: 24 January 2014 CHMP recommends EU approval of a new formulation of Roche’s MabThera for patients with non-Hodgkin lymphoma Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve MabThera (rituximab) 1400mg solution for subcutaneous (SC) ... more
Published on: 21 January 2014 Reminder: Invitation to Roche's Full Year Results for 2013 Roche will publish its Full Year Results for 2013 prior to the opening of the Swiss Stock Exchange on 30 January 2014. more
Published on: 21 January 2014 Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia Two phase III studies evaluating bitopertin for persistent, predominant negative symptoms of schizophrenia did not meet their primary endpoints; third study is ongoing. more